The role of tumour necrosis factor alpha (TNFα) in obesity. by Morris, Alison Mary
THE ROLE OF TUMOUR NECROSIS FACTOR
ALPHA (TNFa) IN OBESITY
Alison Mary Morris, B.Sc (Hons)
A thesis submitted to Adelaide University






1.2.3 Types of Obesity
1.2.4 Obesity related diseases
1.2.5 Determining Obesity ............... .........5
1.2.6 Benefits of weight loss in obesity ........................6
1.3. Insulin resistance and type II diabetes
1.3.1 Role of Insulin.. ..............6
1.3.2 Defining insulin resistance.. .,,..........7
1.3.3 How insulin resistance develops into type II diabetes .........8
1.3.4 Molecular defects involved in Insulin Resistance ....................... 10
....................... 101.3.5 The Insulin Cascade
1.3.6 Risk factors for developing insulin resistance.. ..................11
1.3.6.a Disruptions to the GLUT4 glucose transport.. ,.,.....,...12
1.3.6.b Disruptions to lipid metabolism result in insulin resistance.. .......13
1.4 Adipocyte metabolism........... ...........14
1.4.1 Adipose tissue mass contro1............... ............... 14
1.4.2 Lipogenesis and Lipolysis .............. ................... 14
1.5 Tumour Necrosis Factor-alpha (TNFa)............... ..,..,.,......17
1.5.1 TNFc¿ gene, protein and receptors... ................ 17
1.5.2 TNFa in obesity and insulin resistance ...........19
1.5.2.t Animal studies....... ...................19
1.5.2.b Human studies....... ...................21
1.5.2.b (i) Adipose tissue and skeletal muscle expression and secretion of Tf[Fc..22
1.5.2.b (ii) Monocyte production of TI\Fc, in human obesity...... .,...,....24
iii
1.5.2.b (iii) Circulating levels of TI\Fo in humans .,,...,...,..,24
1.5.3 Polymorphisms in the TNT'ø promoter.. ..,..,..,26
1.5.4 Negative findings with TNFc¿ neutralisation in humans............... .......28
1.5.5 Actions of TllFcr, 29
1.5.5.a How does TNFo interfere with insulin signalling? ,..,,29
1.5.5.b The action of TNFa on enzymes involved in lipid metabolism.......................31
1.5.5.c Apoptosis induced by TNFo ......................32
1.5.5.d Indirect actions of TNFa.... .....32
1.6 TNFa Receptors ..............34
1.6.1 Actions of the TllFo receptors
1.6.2 TNFo Receptors, obesity and insulin resistance.......
1.7 TNFcr interacting with other adipocyte derived factors..... ................37
1.7.1 Interactions between TNFo and other cytokines ..............38
L.7.2.Actions of TllFa on leptin production ............39
1.7.3 Actions of ThlFo on plasminogen activator inhibitor-l (PAI-l) .........39
1.8 The action of TZDs on TNFcr.. ..........41
L.9 Does TNFcI have a pivotal role in limiting fat mass?. .,...,..42
1..10 Summary and aims of the thesis ......................43
Chapter 2: General Methods ................... I
2.1 Study Design
2.1.1 Clinical Weight Loss Studies
2.1.2 Additional Subjects.............. ............1
2.1.3 Subjects recruited for weight loss studies................. ............3
2.1.4 Inclusion Criteria ...........3
2.1.5 Dietary Information for Subjects.............. .........4
2.1.6 Diet Analysis for \ileight Loss Studies................. .................4
2.2 Study Protocol ..................5
2.2.1 Blood Sample Collection ....................... 7
2,2.2 Oral Glucose Tolerance Test (OGTT) .................. 7
2.2.3 Weight, waist circumference and height measurements
2,2.4Blood pressure
2.2.5 Dual-energy X-ray absorptiometry for measuring Body Composition...................8
2.3 Analysis of Blood Samples... ................9
2.3.1 Cobas-Bio Analysis ......................... 9





2.4 Peripheral Blood Mononuclear Cell (PBMC) preparation..................................10
2.4.1 PBMC isolation....
2.4.2 Cell Count and Incubation with TIt{Fa secretagogue................. ..........10
2.4.3 Percentage of monocytes in cell suspension ........
2.5 Determining Production of TNFc from PBMC.............. .................... 11
2.6 Abdominal adipose tissue Biopsies ...................12
2.6.1 Biopsy procedure
2.7 RNA extraction t2
2.7.1RNA extraction. t2
2.7.2 RNA Quantitaion .........13
2.8 Quantitation of TNFc¿ mRNA..... ......................13
2.8.1 Reverse Transcription............ ........13
2.8.2 PCR Ämplification .............. ........... 14
2.8.3 Standard curve construction................ ............ 18
2.9 Genomic DNA Extraction... .................... 18
2.L0 TNFo NcaI Polymorphism ............19
2.lù.1Amplification of genomic DNA ......................19
2,10,2 PCR Conditions......... ...................20
2.10.3 RFLP Analysis ...........21
2.1 I Statistics............
Chapter 3: In vitro production of TNFa by P8MCs.............. ............... I
3.1 Introduction ......................1
3.1.1 TNFo production.....
3.1.2 Monocyte production of TNFø in type II diabetes. .................... 2
3.1.3 Monocyte production of TNFo in obesity .........3
3.1.4 Monocyte production of TNFo with weight loss





3.2.2 PBMC stimulation by LPS 6
7
9




3.3.2 Weight loss and diet...............
3.3.3 Metabolic differences between non-diabetics and type II diabetics.......................11
3.3.4 Weight loss and the effects of diabetes and gender......... t2
3.3.4 Weight loss and changes in metabolic parameters............... ................13
vVariable................ ................... L5
3.3.5 DietarA influence on TNFa production from PBMCs ................ .........15
3.3.6 Associations between TNFo production and obesity ........15
3.3.7 Weight loss and TllFc¿ production from PBMC
3.3.8 Correlations between TNFo and lipids
3.3.9 Correlations between plasma insulin and TNFo production
3.3.10 Correlations between plasma glucose and TNFo production from PBMCs.......20
3.3.11 Correlations between SBP and TNFo production from P8MCS.................,.,,.,.,21
3.4 Discussion....
3.4.1 Monocyte production of TNFcr in obesity and insulin resistance ..,,,..22
3,4.2 The effect of obesity and weight loss on TllFo production by PBMCs ................. 23
3.4.3 Associations with glucose and insulin and TNFo production from P8MCs.........25
3.4.4 Different factors that could potentially affect TNFc production from PBMCs..,26
3.4.5 Gender effects on TNFo production ..,...,.,......,27
3.4.6 Blood Pressure and TNFo .,,,..,,.,.,.27
3.5 Critical Method Evaluation .............28
3.5.1 Concentration of LPS used to stimulate PBMCs..... ..........28
3.6 Conclusion and Summary .,....,,,..,,,,29
Chapter 4: TNFcr, mRNA expression in adipose tissue .........1
4.1 Introduction ......................1
4.1.1 TNFa mRNA expression in adipose tissue .1
4.1.2 Associations between TNFc mRNA expression in adipose tissue and obesity........1
4.1.3 Chapter Aim....... ............3
4.2.1 Subject Characteristics
4.2.2ßat Biopsies
4.2.3 Method of RNA extraction..










4.3.2 Weight loss and diet............. .............7
4.3.3 Changes in metabolic parameters with weight Ioss............ ....................7
4.3.4 TltlFg mRNA abundance in adipose tissue .....10
4.3.5 Associations between TNFcl, mRNA expression and adiposity...............................12
4.3.6 Associations between TNFa mRNA abundance and metabolic variables............15
vi
4.4 Discussion.......... ...............17
4.4.1 IIow is adipose tissue TNFc mRÀ[A abundance associated with obesity..............17
4.4.2Yanations in TNFc¿ mRNA expression in adipose tissue between subjects..........18
4.4.3.Why does weight loss alter TNFø mRNA abundance in adipose tissue?..............19
4.4.4 Associations between TNFø mRNA and metabolic parameters............................20
4.5 Critical Method Evaluation ...,,,.......22
4.5.1 Adipose tissue biopsies.
4.5.2 Methods of quantifying mRNA
4.6 Summary and conclusion ..................25
CHAPTER 5: 
-308 NcoI TNFCT RFLP..... ............. 1
5.1 Introduction ..................... I
5.1.1 Defining polymorphisms....... ...........1
5.1.2 Function of the 
-308 TNFa RFLP........ .............3
5.1.3 -308 TIrlFa RFLP and obesity .........3
5.1.4 Frequency of the 





5.2.1. (a) Subjects involved in weight loss studies
5.2.1. (b) Subjects recruited only for RFLP analysis ................7
5.2.1. (c) Subjects in whom PBMC production of TNFo was also measured..,,.,,.,,,,.,.7
5.2.1. (d) Subjects in whom TNFcr, expression in adipose tissue was also measured....8
5.2.2 Statistics and Data Analysis
.............10
5.3.1 Allele frequency 10
5.3.2 Baseline characteristics......... .....,..,12
5.3.3 Allele frequency of subjects involved in weight loss trials ...................15
5.3.4 Diet analysis based on genotype
5.3.5 Clinical and metabolic parameters during weight Ioss............
5.3.6 Gender and diabetes status differences with weight loss .........
5.3.7 Associations with genotype and weight loss ............ ........... 19
5.4.8 A.ssociations with genotype and systolic blood pressure ......................23
5.3.9 Differences in genotype grouping... ..................23
5.3.10 TNFct production from PBMCs in relation to the NcoI RFLP ....,,,,,24




5.3.12 Changes in percent total body fat and abdominal fat based on the NcoI RFLP 25
5.4 Discussion
5.4.1 Allele frequency ...... ......26
5.4.2 Associations between 
-308 TNFc¿ RFLP and obesity .,.,..,.27
5.4.3 Weight loss and 
-308 TNFo RFLP........ ,...,.....29
5.4.4 
-308 TNFo RI'LP associations with factors influencing syndrome X...................30
5.4.5 
-308 TNFo RI'LP and TNFcr production from PBMCs and mRI\A expression.3l
5.5 Conclusion.......... .............32
Chapter 6: General Discussion............ ..........,......... I
6.1 Overview............ ................1
6.2 Summary of findings.......... ................1
6.2.1 Associations between TNFc¿ and obesity ...........3
6.2.2Eow Tl[Fo responds to weight loss ............ .......3
6.2.3 Associations of TNFo production with metabolic variables.....................................5




6.3.1 What is the main source of circulating TI\IFø?... ...............10
6.3.2 Clarifying the role of TNFcr production by different tissues ... ...,...,..,. t2
6.3.3 TNFo and the interaction with other adipocyte derived factors ........ 13
6.4 Limitations and suggestions for future directions of research............................. 14
6.4.1 Other adipocyte derived factors....... ................ 15
6.4.2 Other RFLPs in the TNFa gene which might be associated................................... 16
ti n
ressure....
8.1.1 Dextran T500- 60/0 ........,...
8.1.2 Counting Fluid for Mononuclear cell number determination.............
8.2 Molecular Biolory Solutions................ ...................... 1











Tumour necrosis factor-alpha (TNFø) is an inflammatory mediator and has also been
described as a possible factor in obesity related insulin resistance and type II diabetes,
although a clear mechanism is still to be elucidated.
This thesis describes six randomised controlled dietary intervention trials that were
performed in free living subjects, with the primary aim of inducing weight loss through
moderate energy restrictive (-6000 KJ/day) diets of varying nutrient composition. Each
study was 12 weeks in duration and all subjects involved were either overweight or obese.
In all studies plasma lipids, glucose, insulin and blood pressure were measured before and
after weight loss.
The first study, described in Chapter 3, involved measuring the production of TNFa by
stimulated peripheral blood mononuclear cells (PBMCs), before and after weight loss, in
obese type II diabetics and non-diabetic controls. There was a fall in production of TNFø
with weight loss and this was more pronounced in males compared with females. There
was no correlation between TNFa production and any msasure of adiposity but there was a
positive association between TNFc production and blood pressure.
In the second study (Chapter 4), TNFa mRNA expression in subcutaneous adipose tissue
was me¿$ured using quantitative real time RT-PCR, both before and immediately after a12
week period of caloric restriction, in obese non-diabetic women. As found with monocyte
production of TNFa, there was no association between baseline TNFa mRNA expression
and obesity but a positive association was observed with blood pressure. TNFa mRNA
lx
abundance was not altered with weight loss. There was great variation in the effect of
weight loss on TNFø mRNA expression, but overall there was a tendency for TNFa
mRNA to be elevated (p:0.06) following weight loss.
The presence of a functional polymorphism (G)l) in the TNFo promoter at position 
-308
was determined in all of the subjects recruited for the six weight loss studies and an
additional small number of obese subjects who did not undergo weight loss (Chapter 5).
The TNF,4 allele in this Australian population was present at a frequency (0.21), which is
comparable to other populations, but there was no difference between genotypes in initial
BMI, the amount of weight lost (GG, 8.1 + 0.65k9; AG,6.9 L 0.l7kg; AA,7.6 + 0.l2kg) or
any metabolic variable.
In summary these studies show that the production of TNFø by PBMCs and expression by
adipose tissue is not associated with obesity. Expression of TNFc in adipose tissue and
monocyte production of TNFa respond differently to moderate weight loss. The
association between TNFo expression and production and blood pressure is one that
should be explored further. The disparate results between animal and human studies
suggest that factors other than TNFo must also be involved in the metabolic changes
associated with obesity.
